If you are at a high risk of dementia or Alzheimer’s disease, it can be consumed, especially emotionally and mentally. In particular, in addition to following a healthy diet and lifestyle, if you think there is little to do to delay the start, you will feel especially enough to sleep. However, a new study on experimental drugs can help to reduce the possibility of Alzheimer’s development of people who are entirely destructive. Of course, Alzheimer is a complicated disease and has no silver bullet treatment.
Published results Lancet Neurology,,, It is a bit complicated and very specific for people in certain groups. In addition, the general population raises many questions from experts on the potential effects of this treatment plan. The following is what you need to know and the doctor thinks about the drug.
Meet an expert: Cliffford segil, DO, I am a specialist in the Providence Saint John’s SAINT John’s S Health Center in Santa Monica, California. Amit Sachdev, Microsoft and Microsoft are medical officers of neuroscience at Michigan State University. Randal J. Batman, MD is a co -author and professor of neurology at St. Louis.
What did the study find?
For this study, the researchers recruited 73 people with rare and inherited genetic mutations that cause overproduction of proteins called amyloid in the brain. If you are not familiar, amyloids are found, but in the brain, they are united to form “plaque” between neurons. The accumulation of these amyloid plaques in the brain can lead to problems related to brain function too much, connected to Alzheimer’s. National Research Institute on Aging (NIA). But we will get more later.
For this study, researchers provided research participants with experimental anti -amyloid drugs. They found that there was no problem with the beginning of the study, and 22 participants who took the drug as the longest (average 8) were 50 % lower the probability of symptoms.
Will treatment treat Alzheimer’s?
Researchers have already studied the effects of treatment on those with Alzheimer’s illness. Instead, they saw people who are very likely to develop within 10 to 15 years before developing the disease based on family history.
Thus, treatment is more suitable for delayed or interruption rather than treating existing diseases.
What is amyloid plaque and what do you do in your brain?
Amyloid plaque is an area of amyloid (again protein). Amit Sachdev, Neurology and medical officer of MD, MS, Michigan State University.
“You can think like a scab on your skin,” he says. “The scab is rough and must be there, and if it becomes too thick, a problem occurs.”
But there is a debate over whether amyloid will help to lower the risk of Alzheimer’s disease. Cliffford segil, DO, Providence St. Jones Health Center in Santa Monica, California. “Targeting brain amyloid is not a slam dunk for Alzheimer’s prevention because there is no clinically used test to predict Alzheimer’s outbreak.”
Dr. Segil said, “Most neurological scientists have a parable of freckles (amyloid plaques) to be normal aging, and very rare have become a skin cancer. You can eat Alzheimer’s bottle. ”
How does this process break down amyloid plaque?
This processing is disassembled using anti-amyloid antibodies, Dr. Sachdev explained.
“Anti-amyloid antibodies are attached to amyloid and remove them using an immune system,” he says. “This is very effective because the immune system is excellent in eliminating things that are not belonged.”
But Dr. Sachdev also says the drug relies on inflammation to remove plaque. (Think about this: Inflammation is a natural physical reaction to the body’s kickstart healing, and it is brought to injuries to repair various cells and biological tools. Treatment appears to cause inflammation.) “More than 50 % of patients exposed to this study have changed in the brain (including swelling and bleeding potential) and may be associated with inflammation.
Thus, these drugs are at risk of brain bleeding, brain edema and brain contraction, and Dr. Segil points out.
Can this treatment be used for the public?
Say that it is not yet Randal J. Batman, MD, co -author and neurology professor at St. Louis Washington University. This is because the study was quite niche. Dr. Bateman said, “Our test was tested as a mutant that causes Alzheimer’s disease in a rare family.
The trial was originally over in 2020. Currently, a trial that will be completed in a few years is in progress, and if they succeed, they can be able to treat the public according to Dr. Bateman.
But some doctors are not sure that these treatments should be used. One of the drugs of treatment (Gantenerumab) is no longer created. Dr. Sachdev said, “The company that develops this company has decided to go in the other direction.
Anti-amyloid drugs are also risk of side effects, including death, and are related to many doctors and families, Dr. Segil says. “As with most neurologists in the United States today, we are not using this drug family,” he says. “Clinical neurologists like me are skeptical that the benefits have continued than the risk of anti -amyloid drugs for dementia.”
KORIN MILLER is a freelancer writer who specializes in general health, gender health and relationships and lifestyle trends. She has a master’s degree from American University, lives on the beach, and someday he owns a teacup pig and a taco truck.
